Department of Neuroradiology, Oxford University Hospital NHS Foundation Trust, UK.
Institute of Radiology, University of Padova, Italy.
Interv Neuroradiol. 2022 Feb;28(1):84-91. doi: 10.1177/15910199211015038. Epub 2021 May 4.
Antiplatelet therapies are commonly used in neurointerventional procedures. However, specific guidelines for their use in these settings is lacking and it can often be difficult to balance the potential risks and benefits of these medications. Considering the continued growth and adoption of neurointerventional procedures, it is crucial to understand the properties of these agents in order to use them safely. Large-scale clinical trials are still needed to clarify many of these aspects for this emerging field. However, the existing literature already provides insight into which antiplatelet drugs are of benefit to the neurointerventionalist as well as their associated risks of ischemic and hemorrhagic complications. Hence, this review focuses on the applications of GPIIb/IIIA inhibitors to neurointerventional procedures.
抗血小板治疗在神经介入手术中被广泛应用。然而，针对这些治疗的具体使用指南尚缺乏，且在权衡这些药物的潜在风险和获益时往往存在困难。考虑到神经介入手术的持续发展和普及，了解这些药物的特性至关重要，以确保安全应用。尽管仍需要开展大规模临床试验来明确这一新兴领域的许多问题，但现有文献已经为神经介入医生了解哪些抗血小板药物有益及其相关的缺血和出血并发症风险提供了帮助。因此，本综述重点关注 GPIIb/IIIa 抑制剂在神经介入手术中的应用。
